Q-omics provides the consensus-scored SCN11A profile across patient tissues and cancer cell-line models. SCN11A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SCN11A is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SCN11A RNA expression shows 17,742 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where SCN11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN11A survival associations across molecular data types. SCN11A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN11A RNA expression–survival associations across cancer types. High SCN11A expression shows favorable associations in KIRP, HNSC, PAAD, LUAD, UVM and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for SCN11A RNA expression.
This table summarizes SCN11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SCN11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN11A shows lower tumor expression in COAD, KIRC, KICH, LUAD, HNSC and THCA. The COAD box plot shows higher SCN11A RNA expression in normal versus tumor tissue (log2 FC = −0.694, t-test p < 0.001).
This table shows molecular features associated with SCN11A in patient tissues and cancer cell lines. In patient samples, SCN11A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
